UCLA researchers developed the technique and measuring device
UCLA biophysicists have developed a new method to rapidly determine a single cell’s stiffness and size — which could ultimately lead to improved treatments for cancer and other diseases. (more…)
Molecule produced by UCLA chemists drove international research collaboration
A synthetic version of a rare toxin produced by a sea creature appears to hold promise for treating many different types of cancer while minimizing the harmful side effects of widely used chemotherapy drugs. (more…)
North Carolina State University researchers have a developed a technique for efficiently producing nanoscale gold rods in large quantities while simultaneously controlling the dimensions of the nanorods and their optical properties. The optical properties of gold nanorods make them desirable for use in biomedical applications ranging from imaging technologies to cancer treatment.
“This technique should facilitate the economical manufacture of large volumes of gold nanorods,” says Dr. Joseph Tracy, an associate professor of materials science and engineering at NC State and senior author of a paper on the work. “And that should be good news for both the science community and the biomedical research and development community.” (more…)
Scientists create nanoscale vehicle to battle cancer without harming healthy cells
A tiny capsule invented at a UCLA lab could go a long way toward improving cancer treatment.
Devising a method for more precise and less invasive treatment of cancer tumors, a team led by researchers from the UCLA Henry Samueli School of Engineering and Applied Science has developed a degradable nanoscale shell to carry proteins to cancer cells and stunt the growth of tumors without damaging healthy cells. (more…)
As cancer treatment in pill form transforms how care is delivered, a new Michigan State University study underscores the challenges patients face in administering their own chemotherapy outside the supervised environment of a cancer clinic.
Chemotherapy pills can target specific cancers better than some traditional intravenous drugs, said Sandra Spoelstra, the MSU assistant professor of nursing who led the study. But they also can be difficult for patients to take. (more…)
Taking a sample from just one part of a tumour may not give a full picture of its‘genetic landscape’, according to a study published in the New England Journal of Medicine.
The findings could help explain why attempts at using single biopsies to identify biomarkers to which personalised cancer treatments can be targeted have not been more successful. (more…)
Patients with metastatic melanoma taking the recently approved drug vemurafenib (marketed as Zelboraf) responded well to the twice-daily pill, but some of them developed a different, secondary skin cancer.
Now, researchers at UCLA’s Jonsson Comprehensive Cancer Center, working with investigators from the Institute of Cancer Research in London, Roche and Plexxikon, have elucidated the mechanism by which the drug excels at fighting melanoma but also allows for the development of skin squamous-cell carcinomas. (more…)
Sara Rockwell is a leader in her field. A professor of therapeutic radiology and pharmacology at the School of Medicine, Rockwell was among the first researchers to study the effects of oxygen deficiency on the response of malignant cells to radiation and anticancer drugs, and was among the first to consider the implications of this deficiency in microscopic tumors for the development of solid malignancies.
Rockwell, who is also associate dean for scientific affairs, joined the faculty of Yale School of Medicine in 1974, and teaches radiation biology, pharmacology, cancer biology, ethics and career development skills. She earned her bachelor’s degree in physics from Penn State University in 1965. She went on to earn her doctorate degree in biophysics from Stanford University in 1971. (more…)
